GBA1 and Parkinson disease: This hypothesis is also supported by the results of a recent clinical trial (ClinicalTrials.gov identifier: NCT02941822), in which the administration of ambroxol led to the improvement of motor functions in both GBA mutations carriers and non-carriers PD patients [41].